PF-Atlas › Weekly Digest › Week 45, 2026

Nerandomilast Gets Its Close-Up, Our Solver Reaches 19 Candidates, and Twelve New Papers Land

October 26 to November 2, 2026 · Active week

Get IPF progress updates by email

This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.

We email a confirmation link first, so it is really you. No spam, ever.

The week in plain words

IPF still has no cure, and no treatment can undo existing lung scarring. Two approved drugs slow the disease, and a newly approved third one, nerandomilast, got fresh scientific attention this week with a study explaining how it affects lung cell behavior. Twelve new research papers arrived, no new clinical trials opened or changed, and our own PF-Atlas discovery engine continued building its list of computer-generated drug-combination hypotheses, now reaching 19 candidates.

Where things stand now

IPF remains an incurable disease. Scarring that has already formed in the lungs cannot be reversed by any available treatment. What doctors can offer today are drugs that slow how fast the scarring spreads. Three options sit in the strongest tier of evidence. Nintedanib and pirfenidone are long-established approved treatments. Nerandomilast, a PDE4B inhibitor that damps down inflammation and the activation of scar-forming cells, received FDA approval in October 2025 and is the newest addition to that group. Inhaled treprostinil and admilparant are in late-stage (Phase III) trials with positive signals but are not yet fully approved. Rentosertib is in earlier human trials. Everything else, including cell therapies and gene delivery approaches, remains experimental or preclinical, meaning it has not yet been proven safe and effective in people.

The best option right now

For a person living with IPF right now, the honest answer is that the best available options are the approved anti-fibrotic drugs, which slow lung function decline but do not stop or reverse the disease. Nerandomilast is the newest FDA-approved choice, joining the existing approved treatments. Inhaled treprostinil and admilparant show promise in ongoing Phase III trials but are not yet approved. No combination of drugs has been proven superior to monotherapy in large trials. Patients should make decisions with their own specialist, because what fits best depends on individual health, side-effect tolerance, and access.

How close are we to regeneration

True regeneration, meaning actually regrowing healthy lung tissue to replace scar tissue, remains a research goal and is not an available treatment. The closest efforts in the data are all experimental or preclinical. The uPAR-CAR-T approach uses engineered immune cells to clear out old, damaged cells that drive scarring, and is still in animal-stage research. The senolytics plus WNT agonist concept would first clear those same damaged cells, then try to coax surviving stem-like cells to repopulate the lung, but this is also only a concept being tested in the lab. An AI knowledge graph is being used to connect findings across IPF, aging, cancer, and regeneration research to find overlooked leads. None of these are ready for patients. Regeneration is a serious scientific direction, but calling it close would not be honest.

Study of the week

The standout paper this week comes from Hamada, Hayashi, Motooka and colleagues, published in the journal Genes to Cells in 2026. They looked at nerandomilast, the drug that was just FDA-approved in late 2025, and asked a more detailed question: what exactly does it do to the cells lining the air sacs in the lung? Those cells, called alveolar epithelial cells, come in different states, and in IPF many of them get stuck in a stressed, abnormal state that promotes scarring. The researchers found that nerandomilast was linked to changes in how those cells move between states, alongside the reduction in fibrotic remodeling (scar tissue buildup) that the drug was already known for. This is important because it gives scientists a clearer picture of the biological mechanism, which could help refine the drug or find combinations that work even better. It does not change what patients can do today, nerandomilast is already approved and this is basic science filling in the details, but it is a meaningful piece of the puzzle.

What changed since last week

No new clinical trials opened this week and no existing trials changed status. Twelve new papers were published, adding knowledge on topics including how chemical tags on proteins called lysine acylations go wrong in IPF, how a blood marker called KL-6 behaves during dangerous flare-ups, how aging cells interfere with the lung's ability to fight viruses, how a pressure-sensing protein called PIEZO1 drives harmful inflammation in immune cells, how a structural protein called type VI collagen is distributed differently around airways in IPF lungs, and how the gut and lungs communicate through the microbiome in ways that might be relevant to respiratory disease. None of these papers represent a change in what is available to patients, but they steadily expand the map of what drives the disease.

Our own search for a cure this week

Every day, PF-Atlas runs its own discovery engine, a genetic-algorithm solver combined with an AI literature scan, that we built and operate ourselves. Its job is to simulate cocktails of already-known drugs, including drugs approved for other diseases entirely, to search for combinations that might help IPF lungs. This is not a clinical trial and these are not proven treatments. They are computer-generated hypotheses that our team and collaborating researchers use to decide what to investigate next in the lab. This week the solver reached 19 total candidate formulas in its active pool, up from previous weeks, with 0 new cross-disease signals and 0 new hypothesis documents finalized this cycle. Four items were added to the pool this week: an ECM-targeted aberrant epithelial repair modulator, a CHIP-mediated TGF-beta-1 degrader inspired by the verbascoside mechanism, verbascoside itself as a TGF-beta-1 degradation agent, and nerandomilast added specifically for its newly detailed effects on alveolar epithelial cell state dynamics that the study of the week described. The solver also produced five new conceptual candidates this week, labeled solverBreakthroughs, which are entirely computer-generated ideas that have not been tested in people: an inhaled OVOL2 mRNA nanoparticle, a semaphorin-3A fusion protein for inhalation, a neuregulin-1 fragment for inhalation, an inhaled gamma-secretase inhibitor called dibenzazepine, and a bispecific synthetic mRNA designed to push cells toward becoming healthy type-1 lung lining cells. The top-scoring formula the solver currently favors combines five ingredients, wnt-rspo3 (a stem cell activator), an ECM remodeling inhibitor, a HOPX activator, curcumin acting on inflammatory pathways TLR4 and NLRP3, and a miR-34a inhibitor, and scores 99 on the solver's internal FVC-preservation metric. That score is a model output only. It means the algorithm thinks this combination is theoretically promising, not that it works in people. We share this openly so the research community can see what directions our engine is pointing toward.

Inside the PF-Atlas lab

Strongest simulated combination so far
WNT/RSPO3 agonist + ECM remodeling inhibitor + HOPX activator + Curcumin (TLR4/NLRP3) + miR-34a inhibitor
In our 24-month computer simulation this cocktail of already-known drugs moved lung function (FVC) toward about 99%. A model result and a research hypothesis, not a treatment.
New candidate ideas the solver found
  • Inhaled OVOL2 mRNA Nanoparticle (LNP-OVOL2)
  • Semaphorin-3A-Fc Fusion (Inhaled)
  • Neuregulin-1 EGF Domain Fragment (NRG1-β1 ECD, Inhaled)
  • Dibenzazepine (DBZ) Inhaled Gamma-Secretase Inhibitor
  • AGER/Podoplanin Bispecific Synthetic mRNA (AEC1 Fate Commitment Therapy)

Everything here is PF-Atlas computer model output, a hypothesis to guide researchers. It is not clinical evidence and not a treatment anyone can take.

Print this to show your pulmonologist →

Sources this week

New studies
  • Pathological regulatory roles of lysine acylation modifications in idiopathic pulmonary fibrosis (Review). · Molecular medicine reports 2026 PMID 42960441 on PubMed ↗
  • Serum KL-6 Levels at Acute Exacerbation in Patients With Interstitial Lung Disease. · In vivo (Athens, Greece) 2026 PMID 42957239 on PubMed ↗
  • Cellular Senescence Dysregulates Antiviral Interferon Responses in Idiopathic Pulmonary Fibrosis. · Aging cell 2026 PMID 42902866 on PubMed ↗
  • The PIEZO1/CISD1/IP3R Mechanotransduction Axis Drives Macrophage Mitochondrial Dysfunction and Inflammatory Activation in Pulmonary Fibrosis. · MedComm 2026 PMID 42889684 on PubMed ↗
  • Nerandomilast is Associated With Altered Alveolar Epithelial Cell State Dynamics While Attenuating Fibrotic Remodeling in Pulmonary Fibrosis. · Genes to cells : devoted to molecular & cellular mechanisms 2026 PMID 42827411 on PubMed ↗
  • Research on the role and mechanism of SLC7A5 in idiopathic pulmonary fibrosis. · Molecular medicine reports 2026 PMID 42825353 on PubMed ↗
  • Advances in prognostic assessment of idiopathic pulmonary fibrosis: From clinical-physiological parameters and molecular biomarkers to multimodal models. · Respiratory medicine 2026 PMID 42822813 on PubMed ↗
  • ROS/HIF-1 signaling in alveolar macrophages: implications for lung fibrosis. · American journal of physiology. Lung cellular and molecular physiology 2026 PMID 42779491 on PubMed ↗
  • Inhibition of extracellular tissue transglutaminase activity attenuates development of pulmonary fibrosis in a novel rabbit model. · American journal of physiology. Lung cellular and molecular physiology 2026 PMID 42779478 on PubMed ↗
  • The gut-lung axis in respiratory diseases: Mechanisms, microbiome dysbiosis, and therapeutic implications. A comprehensive review. · Respiratory medicine 2026 PMID 42778035 on PubMed ↗
  • Corrigendum to "Evaluation of radiological lung pattern and disease progression in patients with asbestosis compared to patients with idiopathic pulmonary fibrosis" [Respir. Med. 262, (2026)]. · Respiratory medicine 2026 PMID 42744670 on PubMed ↗
  • Type VI collagen is proportionally lower around airways and blood vessels in idiopathic pulmonary fibrosis. · American journal of physiology. Cell physiology 2026 PMID 42743047 on PubMed ↗
  • Association of emergency room visits with outcomes in idiopathic pulmonary fibrosis: A brief report from the pulmonary fibrosis foundation registry. · Respiratory medicine 2026 PMID 42722092 on PubMed ↗
  • Novel therapies for refractory idiopathic inflammatory myopathy-associated interstitial lung disease. · Current opinion in rheumatology 2026 PMID 42712119 on PubMed ↗
  • Extended static preservation of donor lungs at 10°C and early post-transplant outcomes: Experience from a center in the US. · JHLT open 2026 PMID 42602443 on PubMed ↗
  • Reply to Jiang: When a key composite endpoint is neutral: should mortality trends drive interpretation? · American journal of respiratory and critical care medicine 2026 PMID 42560853 on PubMed ↗
  • A CT-based score for predicting histopathological usual interstitial pneumonia features and predicting disease progression in smokers with fibrotic idiopathic interstitial pneumonia. · European radiology 2026 PMID 42470480 on PubMed ↗
  • miR-205-5p accelerates lung fibroblast senescence in IPF patients via mediation of mitochondrial dynamics. · Mitochondrion 2026 PMID 42365869 on PubMed ↗
  • Development of a dual-mode immunoassay kit for periostin detection in exhaled breath condensate using α-NaYF(4)@ZIF-67 core-shell nanostructures. · Biosensors & bioelectronics 2026 PMID 42341698 on PubMed ↗
  • Artemisinin and quercetin attenuate hydrogen peroxide-induced oxi-inflammatory-mitochondrial dysfunction-SASP axis mediated lung epithelial cell premature senescence via targeting Stat-1/Atm-p53/p16/p21/Bcl2, NOD-1/MAPKs/NF-κB/ signalling cascades. · Tissue & cell 2026 PMID 42296779 on PubMed ↗
Get IPF progress updates by email

This is not a newsletter. It is the real movement in the fight against idiopathic pulmonary fibrosis. New trials opening, new treatments being tested, where the best options stand now, in plain language, once a week. If you or someone you love is living with IPF, this is the progress you want to follow. Confirm your address to start. Unsubscribe anytime.

We email a confirmation link first, so it is really you. No spam, ever.
Medical disclaimer. This digest summarizes public clinical-trial and research data in plain language for information only. It is not medical advice, a treatment recommendation, or a promise of any outcome. Evidence changes; treatments described as investigational are not proven cures. Always verify with ClinicalTrials.gov, PubMed and a qualified pulmonologist before any decision.